10 Best Biotech Stocks with Highest Upside Potential
On April 16, reports from J.P. Morgan's biopharma and medtech venture and licensing studies indicated that the capital markets began the year 2026 with selective strength.
Legend Biotech Corp (LEGN)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | IvyRock Asset Management Charles Huang | 804,000 | $14,544,360 | 8.17% | |
| 2. | Walleye Capital Will England | 235,415 | $4,258,657 | -22% | 0.02% |
| 3. | 70,100 | $1,268,109 | -27% | 0.01% | |
| 4. | 63,400 | $1,146,906 | -23% | 0% | |
| 5. | Bayforest Capital Theodoros Tsagaris | 3,528 | $63,822 | 0.07% |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.77 | 9,936 | $87,138.72 | 247,438 | 2026-03-25 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,763,475 | $104,261,271 | 0.44% | |
| 2. | 925,920 | $16,749,893 | 6.8% | |
| 3. | 470,292 | $8,507,582 | 0.04% | |
| 4. | 300,958 | $5,733,250 | 0.35% | |
| 5. | 305,214 | $5,521,322 | 0% |
News See All
10 Stocks With Double-Digit Returns
Ten stocks kicked off the trading week with double-digit gains, defying a lackluster performance on the broader market, as investors turned to positive developments to bolster their buying appetite.
10 Overlooked Growth Stocks to Buy Now
On April 14, Tom Lee, Fundstrat's Head of Research, joined CNBC's 'Power Lunch' to discuss his outlook on equities.
RBC Capital Cuts PT on Legend Biotech Corporation (LEGN) to $62 From $66 - Here's Why
Legend Biotech Corporation (NASDAQ:LEGN) is one of the best high growth healthcare stocks to buy now.
11 High Growth Healthcare Stocks to Buy Now
On March 26, Stephanie Link, Hightower chief investment strategist, appeared on CNBC's ‘Squawk Box’ to talk about the latest market trends, where investors can find opportunities, and the effects ...
Barclays Cite Favorable Long-Term Outlook For Legend Biotech Corporation (LEGN) Despite Near-Term Expectation Revisions
TheFly reported on February 4 that Barclays lowered its price target on LEGN to $80 from $90 and maintained an Overweight rating on the shares. Although the long-term forecast for the company's clinical...
FDA Guidance on MRD Negativity Bodes Well for Legend Biotech (LEGN)
On January 20, Leonid Timashev of RBC Capital maintained an Outperform rating on Legend Biotech (NASDAQ:LEGN) and set a $66 price target.
15 Innovative Healthcare Stocks to Buy According to Analysts
Over the last two years, artificial intelligence has propelled global financial markets into a boom, with stocks reaching all-time highs.
17 Biotechnology Stocks with More Than 50% Upside
2025 was a year characterized by both challenges and opportunities for the biotechnology sector.
Legend Biotech (LEGN) Shakes Up Board
In a board shakeup last month, Legend Biotech Corp (NASDAQ:LEGN) appointed chairman and executive director of a major shareholder, GenScript, Robin Meng, as a Class III director to serve until the company...